AEYE Health
AEYE Health uses fully autonomous AI to bring fast, accessible diabetic eye exams to primary care and other points of care, helping prevent blindness for millions of people with diabetes.
Problem & solution
Diabetic retinopathy is a leading cause of blindness, yet most people with diabetes do not receive their recommended annual eye exam due to access, specialist referrals and other barriers. AEYE-DS brings the exam directly to points of care such as primary care. AEYE-DS is a fully autonomous AI requires just one image per eye, no dilation or physician interpretation, and provides an immediate diagnostic result and a sight-saving exam. It closes care gaps, boosts HEDIS/MIPS and is reimbursable.
Primary customers & users
AEYE-DS is purchased by health systems, primary care groups, endocrinology practices, payers and other organizations managing diabetic populations. Decision-makers include clinical, population health and quality leaders. Medical assistants, nurses and other clinical staff use AEYE-DS at the point of care, no need for physician interpretation.
Differentiation
AEYE-DS is fully autonomous AI. Unlike decision support AI solutions, AEYE-DS is cleared by the FDA to diagnose without any physician interpretation, unlike tele-retina platform that employ eye specialists. AEYE-DS is the only FDA approved AI that can be used anywhere, using a portable device and using just one image per eye, without dilation.
Current traction
AEYE-DS is today the fastest-growing solution for diabetic eye exams in the United States. It is used across all 50 states by dozens of institutional health systems, performing thousands of eye screenings daily and helping prevent blindness for many patients every single day.
How Summit participants can help
AEYE Health would love to connect with health systems, primary care networks, and strategic partners to expand access to AEYE-DS across the country.